Clinical Trials Logo

Clinical Trial Summary

26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given intravenously on day 1 of each 3 weekly cycle prior to radical cystectomy, to evaluate the overall response rate and to determine whether this approach warrants further research of a phase II/III study.Participation in 2 sub studies will also be offered to the participants. 1. Contrast Magnetic resonance imaging (MRI ) scans will be taken at baseline and after cycle 1 and cycle 3. 2. A pilot sub study involving the circulating tumour cell concentration from blood samples taken at baseline, prior to each cycle of chemotherapy and prior to surgery


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Infiltrating Bladder Urothelial Carcinoma

NCT number NCT01616875
Study type Interventional
Source University Hospitals Bristol NHS Foundation Trust
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 2012
Completion date January 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT02944357 - Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery N/A
Active, not recruiting NCT01495676 - A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer N/A
Withdrawn NCT03419130 - Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Phase 2
Withdrawn NCT03238664 - Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors N/A
Active, not recruiting NCT03549715 - NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma Phase 1/Phase 2
Terminated NCT02767921 - sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer Phase 1
Recruiting NCT03609216 - Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations Phase 2
Withdrawn NCT02688348 - Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer N/A